How Does Mounjaro Work? The Science Behind Tirzepatide
Key point: Mounjaro (tirzepatide) is the first medicine to simultaneously activate both the GIP and GLP-1 receptors. This dual action produces appetite suppression and weight loss that is significantly greater than medicines targeting only the GLP-1 receptor — such as semaglutide (Wegovy) or liraglutide (Saxenda) — achieving an average of 20.9% body weight reduction in clinical trials.
Introduction: a new class of medicine
To understand why Mounjaro is more effective than earlier injectable weight-loss treatments, it helps to understand the hormonal system it acts upon. The gut produces a series of peptide hormones in response to food. These hormones communicate with the brain, pancreas, and digestive system to regulate hunger, satiety, blood sugar, and fat metabolism.
All previous GLP-1-based medicines — including liraglutide (Saxenda) and semaglutide (Wegovy) — target a single receptor: the GLP-1 receptor. Tirzepatide, the active ingredient in Mounjaro, is structurally based on the GIP hormone but engineered to bind with high affinity to both the GIP receptor and the GLP-1 receptor. This dual action is what sets it apart.
For an overview of eligibility, dosing, and how to access the treatment, see: What Is Mounjaro? Tirzepatide for Weight Loss Explained.
GLP-1 receptor activation explained
Glucagon-like peptide-1 (GLP-1) is a hormone released by L-cells in the small intestine and colon in response to food. It plays a central role in the body’s post-meal response and has several important effects:
- Signals fullness to the brain: GLP-1 acts on the hypothalamus and brainstem to reduce appetite and promote satiety.
- Slows gastric emptying: Food moves more slowly from the stomach to the small intestine, prolonging the feeling of fullness after meals.
- Stimulates insulin secretion: GLP-1 enhances glucose-dependent insulin release from the pancreatic beta cells, improving blood sugar control without causing hypoglycaemia in non-diabetic individuals.
- Suppresses glucagon: Glucagon is the hormone that raises blood glucose; GLP-1 suppresses its secretion, contributing to lower post-meal blood sugar.
In people with obesity, GLP-1 signalling is often blunted, meaning the natural appetite-regulating system is less effective. By providing a pharmacological GLP-1 signal, tirzepatide restores and amplifies these satiety cues.
GIP receptor activation explained
Glucose-dependent insulinotropic polypeptide (GIP) is the second gut hormone targeted by tirzepatide. It is released from K-cells in the upper small intestine shortly after eating. GIP was historically considered primarily an incretin hormone — one that augments insulin secretion in the presence of elevated blood glucose.
For many years, GIP was viewed as a potential target for blocking rather than activating in obesity treatment, because isolated GIP receptor activation appeared to promote fat storage. However, research has since shown that when GIP and GLP-1 receptors are activated simultaneously, the effect on fat tissue is reversed: instead of storing fat, the body is prompted to mobilise it.
GLP-1 receptor
Signals fullness to the brain, slows digestion, stimulates insulin, suppresses glucagon. Single target of Saxenda and Wegovy.
GIP receptor
Enhances insulin secretion, and — when activated alongside GLP-1 — promotes fat mobilisation rather than fat storage. Unique to tirzepatide.
The simultaneous activation of both receptors by tirzepatide produces a synergistic effect that is demonstrably greater than activating either receptor alone. This is the mechanistic basis for Mounjaro’s superior clinical outcomes.
The dual advantage: synergistic effects
When the GIP and GLP-1 receptors are activated at the same time, the combined effect on appetite and metabolism is substantially greater than the sum of each action in isolation. The principal consequences of dual receptor activation include:
- Stronger appetite suppression: Central signalling via both the GLP-1 and GIP pathways produces a more pronounced reduction in hunger drive than either pathway alone.
- Fat mobilisation: The GIP–GLP-1 combination shifts adipose tissue from a fat-storage to a fat-releasing state, contributing to greater fat mass reduction.
- Prolonged satiety: Slower gastric emptying combined with central appetite suppression means patients feel satisfied for longer between meals and consume less food overall.
- Superior glucose control: Dual incretin action improves insulin sensitivity and reduces fasting and post-meal blood glucose more effectively than GLP-1 agonism alone.
Appetite suppression in practice
One of the most clinically significant effects of Mounjaro is its impact on what patients commonly describe as “food noise” — the near-constant mental preoccupation with food, hunger, and eating that many people with obesity experience. This is not simply about willpower; it reflects altered central appetite regulation driven by hormonal and neurochemical factors.
By amplifying both GLP-1 and GIP signals in the hypothalamus, tirzepatide substantially reduces this mental preoccupation. Patients frequently report that food becomes less compelling, that they feel satisfied with smaller portions, and that they are less likely to seek out high-calorie foods between meals.
- Reduced hunger between meals, particularly in the hours before a meal is due
- Earlier onset of fullness during eating — smaller portions feel satisfying
- Reduced cravings for high-fat, high-sugar, and ultra-processed foods
- Decreased “food noise” — less mental energy spent thinking about food
- Lower hedonic reward response to calorie-dense foods
- Improved ability to follow a calorie-reduced diet without persistent hunger
It is important to note that these effects support — but do not replace — dietary and behavioural change. Mounjaro is licensed for use alongside a reduced-calorie diet and increased physical activity. Patients who actively engage with lifestyle changes consistently achieve better outcomes than those who rely on the medication alone.
Metabolic effects beyond weight loss
Mounjaro produces a range of metabolic improvements that extend beyond weight reduction. These effects are clinically relevant both for patients with type 2 diabetes and for those with obesity-related comorbidities such as hypertension or dyslipidaemia.
↓HbA1c
Significant reductions in long-term blood glucose in patients with type 2 diabetes
↓BP
Clinically meaningful reductions in systolic blood pressure in trial participants
↓LDL
Improved blood lipid profile including reductions in LDL cholesterol
↓Liver fat
Reductions in hepatic fat content, relevant to non-alcoholic fatty liver disease
These cardiometabolic improvements are in part a direct consequence of weight loss, but research suggests that some — particularly the improvements in insulin sensitivity and glucose metabolism — are also mediated directly by GIP and GLP-1 receptor activation, independent of weight reduction.
Expected timeline of effects
The effects of tirzepatide build gradually as the dose is escalated. The following timeline reflects typical patient experience, though individual responses vary.
1
Weeks 1–4 (2.5 mg): early adaptation
The starting dose is primarily a tolerability dose. Many patients notice mild nausea, reduced appetite, or earlier satiety. Significant weight loss is not expected at this stage. The body begins to adapt to the hormonal signalling changes.
2
Weeks 5–8 (5 mg): appetite begins to reduce
At the first maintenance dose, most patients experience a noticeable reduction in appetite and food intake. Some begin to lose weight meaningfully at this stage. Gastrointestinal side effects, if present, typically peak during the first escalation and then diminish.
3
Months 3–6 (7.5–10 mg): consistent weight loss
As the dose increases through the mid-range escalation steps, weight loss typically becomes more consistent and measurable. “Food noise” diminishes noticeably for many patients. Energy levels may improve as metabolic health begins to recover.
4
Months 6–18 (12.5–15 mg): progressive results
The greatest cumulative weight loss is observed during this period at the higher doses. The SURMOUNT-1 trial measured its primary endpoint at 72 weeks (approximately 18 months), when the 20.9% average weight loss figure was recorded. Patients who reach this stage and continue treatment consistently achieve the best outcomes.
What happens when you stop Mounjaro?
Important: Obesity is a chronic condition. SURMOUNT-4 demonstrated that stopping Mounjaro after achieving significant weight loss results in the regain of approximately two-thirds of the lost weight within 52 weeks. Mounjaro is not a short-course treatment to be discontinued once a target weight is reached — it is a long-term management tool for a chronic condition, in the same way that antihypertensives are not stopped once blood pressure normalises.
When tirzepatide is stopped, the GIP and GLP-1 receptor signalling it provides ceases. Appetite returns to pre-treatment levels, food noise re-emerges, and the hormonal environment that supported reduced calorie intake is removed. Without the concurrent maintenance of substantial dietary and lifestyle changes, weight regain is the expected outcome for most patients.
Decisions about the duration of treatment should be made collaboratively with a prescriber, taking into account ongoing weight maintenance, tolerability, and individual health goals. Some patients may be able to maintain weight at a lower dose; others will require continued treatment at their established dose.
Interested in starting Mounjaro?
Access Doctor is a GPhC-registered online pharmacy (no. 9011198) offering online consultations with GMC-registered GPs. Complete your free assessment to find out if you are eligible.
View weight loss treatmentsFrequently asked questions
Does Mounjaro affect the brain directly?
Yes. GLP-1 and GIP receptors are expressed in the central nervous system, particularly in the hypothalamus and brainstem — the regions responsible for appetite regulation and energy homeostasis. Tirzepatide crosses the blood-brain barrier and acts directly on these receptors, which is why it produces such a pronounced reduction in appetite and food cravings, not merely a peripheral slowing of digestion.
Why is Mounjaro more effective than Saxenda or Wegovy?
Saxenda (liraglutide) and Wegovy (semaglutide) target only the GLP-1 receptor. Mounjaro additionally activates the GIP receptor, producing a synergistic effect that is significantly greater than GLP-1 agonism alone. The dual mechanism results in stronger appetite suppression, greater fat mobilisation, and superior metabolic improvements, reflected in the clinical trial data showing approximately 20.9% average weight loss at 15 mg compared to ~8% for liraglutide and ~15% for semaglutide 2.4 mg.
Does Mounjaro cause muscle loss as well as fat loss?
Rapid weight loss from any cause can result in some loss of lean muscle mass alongside fat. In the SURMOUNT trials, the majority of weight lost was fat mass, but muscle mass loss was also observed. This is why it is strongly recommended to maintain adequate protein intake (at least 1.2 g per kilogram of body weight daily) and engage in resistance exercise during treatment to preserve lean mass.
How does Mounjaro affect insulin and blood sugar?
Mounjaro stimulates insulin secretion in a glucose-dependent manner — meaning it only enhances insulin release when blood glucose is elevated. This reduces the risk of hypoglycaemia in non-diabetic patients. It also improves insulin sensitivity and suppresses glucagon, contributing to lower fasting and post-meal blood glucose. In patients with type 2 diabetes, these effects are clinically meaningful and may allow a reduction in other diabetes medications.
Will my appetite return to normal if I reduce the dose?
Reducing the dose may result in some increase in appetite, as the degree of GIP and GLP-1 receptor stimulation is dose-dependent. Some patients successfully maintain weight at a lower dose, while others find that their appetite and food intake increase significantly at sub-therapeutic doses. Dose decisions should be made with your prescriber based on your response and tolerability.
Is the weight loss permanent after stopping Mounjaro?
Evidence from SURMOUNT-4 indicates that most patients regain a substantial proportion of lost weight after stopping treatment. This does not reflect a failure of the medicine; it reflects the nature of obesity as a chronic condition driven by biological factors that reassert themselves when pharmacological support is withdrawn. Long-term treatment, or the establishment of substantial and sustainable lifestyle changes, is typically necessary to maintain the achieved weight loss.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
- Finan B, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151.
- Eli Lilly. SURMOUNT-4: tirzepatide vs placebo following tirzepatide-induced weight loss. JAMA. 2023;330(22):2151–2161.
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
- Medicines and Healthcare products Regulatory Agency. Mounjaro: summary of product characteristics. November 2023. www.medicines.org.uk
- National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity (TA1026). London: NICE; 2024. www.nice.org.uk/guidance/ta1026
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Mounjaro is a prescription-only medicine (POM); it must be prescribed by a qualified healthcare professional following an individual clinical assessment. Do not start, stop, or alter any prescribed medication without consulting your prescriber. If you experience any side effects, contact your prescriber or call NHS 111. In an emergency, call 999.